Tumors of the Central Nervous System, Volume 5
Kurzinformation
inkl. MwSt. Versandinformationen
Artikel zZt. nicht lieferbar
Artikel zZt. nicht lieferbar

Beschreibung
The most recent developments in diagnostic and therapeutic aspects of Gliomas (glioblastoma) in the brain are presented. The importance of personalized medicine and clinical validation for targeted therapy are discussed. The identification of various types of biomarkers (determined by molecular genetics) is included, along with their advantages and limitations as markers in tumor detection and diagnosis. The identification and validation of brain cancer (glioblastoma) genes are discussed. The role of cancer stem cells in the initiation and persistence of malignant gliomas is explained; response of glioblastoma cancer stem cells to various growth factors, such as epidermal growth factor receptor kinase inhibitor, is explained. The use of surgical resection, chemotherapy (e.g., temozolomide), immunotherapy, and radiation therapy for glioblastoma patients is included. Biological impediments for chemotherapy and radiotherapy for malignant glioblastoma are pointed out. Standard (established) as well as newer imaging modalities (proton magnetic resonance spectroscopy) are discussed. Also included are proton magnetic resonance spectroscopy in intracranial gliomas, and the use of proton magnetic spectroscopic imaging in determining the infiltration zone in gliomas. The role of molecular signaling in the CNS cancer development is explained, including cell death signaling in glioblastoma multiforme. The most recent developments in diagnostic and therapeutic aspects of Gliomas (glioblastoma) in the brain are presented. The importance of personalized medicine and clinical validation for targeted therapy are discussed. The identification of various types of biomarkers (determined by molecular genetics) is included, along with their advantages and limitations as markers in tumor detection and diagnosis. The identification and validation of brain cancer (glioblastoma) genes are discussed. The role of cancer stem cells in the initiation and persistence of malignant gliomas is explained; response of glioblastoma cancer stem cells to various growth factors, such as epidermal growth factor receptor kinase inhibitor, is explained. The use of surgical resection, chemotherapy (e.g., temozolomide), immunotherapy, and radiation therapy for glioblastoma patients is included. Biological impediments for chemotherapy and radiotherapy for malignant glioblastoma are pointed out. Standard (established) as well as newer imaging modalities (proton magnetic resonance spectroscopy) are discussed. Also included are proton magnetic resonance spectroscopy in intracranial gliomas, and the use of proton magnetic spectroscopic imaging in determining the infiltration zone in gliomas. The role of molecular signaling in the CNS cancer development is explained, including cell death signaling in glioblastoma multiforme. von Hayat, M. A.
Produktdetails
So garantieren wir Dir zu jeder Zeit Premiumqualität.
Über den Autor
- Taschenbuch
- 635 Seiten
- Erschienen 2019
- WORLD HEALTH ORGN
- Gebunden
- 797 Seiten
- Erschienen 2016
- Elsevier
- paperback
- 523 Seiten
- Erschienen 2015
- American Registry of Pathology
- Taschenbuch
- 368 Seiten
- Erschienen 2019
- IARC
- hardcover
- 760 Seiten
- Erschienen 2024
- Academic Press
- Taschenbuch
- 355 Seiten
- Erschienen 2017
- WORLD HEALTH ORGN
- Taschenbuch
- 400 Seiten
- Erschienen 2016
- International Agency for Re...
- Taschenbuch
- 410 Seiten
- Erschienen 2015
- WORLD HEALTH ORGN
- Kartoniert
- 304 Seiten
- Erschienen 1985
- Springer
- paperback
- 736 Seiten
- Erschienen 2003
- Oxford University Press, U....
- hardcover
- 128 Seiten
- Erschienen 2014
- Thieme Medical Publishers
- paperback
- 634 Seiten
- Erschienen 2000
- Springer
- Kartoniert
- 336 Seiten
- Erschienen 2017
- Wiley-VCH
- hardcover
- 359 Seiten
- Erschienen 2016
- Springer




